Nyxoah (NYXH) Q2 2026: U.S. Net Revenue Jumps 25% as Genio Adoption Expands

2026-07-08 | By EarningsIQ Research

Nyxoah’s U.S. launch delivered a 25% sequential revenue surge, driven by expanding surgeon adoption and robust payer approvals. Gross margin softness from production yield issues weighed on profitability, but management reaffirmed a disciplined cost approach and margin recovery path. With reimbursement clarity and a deepening commercial footprint, Nyxoah signals confidence in accelerating adoption and scaling toward break-even.

Summary

• Genio U.S. Penetration Accelerates: Market share grows in high-volume accounts as new sales reps ramp quickly.
• Margin Recovery Plan in Focus: Yield issues temporarily pressure gross margin, but cost levers and product upgrades are expected to restore profitability.
• Reimbursement Clarity De-risks U.S. Growth: Both CMS and commercial payer frameworks support continued adoption through 2027.

Business Overview

Nyxoah is a medtech company specializing in neurostimulation solutions for obstructive sleep apnea (OSA). Its flagship product, Genio, is a hypoglossal nerve stimulation (HGNS) system designed to treat OSA patients who cannot tolerate CPAP therapy. The company generates revenue through device sales and related disposables, with its business segmented into U.S. and international markets. U.S. commercialization, launched in late 2025, is now the primary growth engine, while established international markets (notably Germany, Middle East, UK, Netherlands) provide a base of recurring revenue.

Performance Analysis

Nyxoah reported 13% sequential worldwide revenue growth, with the U.S. segment delivering a standout 25% sequential gain as Genio adoption accelerated. The U.S. now represents the majority of revenue, underpinned by a disciplined commercial rollout—highlighted by the addition of 15 new sales reps (now 40 in total) and 62 more surgeons trained during the quarter. Active accounts rose to 91 of 125 targeted, and the patient pipeline nearly doubled quarter over quarter, with 241 patients submitted for prior authorization versus 116 at year-end.

Gross margin declined to 57%, down from 62% a year ago, attributed to production yield issues that have since been addressed. Operating expenses rose as expected, reflecting ongoing investment in U.S. commercial infrastructure and market access. Notably, non-GAAP cash operating expenses were kept in check sequentially, as management shifted resources from R&D and G&A toward U.S. sales execution. International results were stable, overcoming typical Q1 seasonality due to strong performance in Germany and new market entries.

• Sales Force Expansion: Fully trained reps now cover 200 of 400 high-volume U.S. accounts, doubling addressable market reach.
• Surgeon Engagement: Total surgeons trained on Genio reached 207, with positive feedback accelerating adoption curves.
• Reimbursement Stability: 100% prior authorization approval rate maintained, with both commercial and Medicare payers providing broad coverage.

Nyxoah’s operational execution in the U.S. is translating into higher market share (12–14% in active accounts), while international discipline supports the company’s break-even ambitions.

Executive Commentary

Strategic Positioning

1. U.S. Commercial Ramp

Nyxoah’s U.S. commercial strategy centers on high-volume account activation, rapid surgeon training, and targeted sales force deployment. The company’s ability to double its effective coverage by onboarding 15 new reps and activating 34 new accounts in Q1 signals operational agility. Early market share capture (12–14% in active accounts) demonstrates Genio’s competitive positioning and supports management’s confidence in accelerating growth through year-end.

2. Reimbursement and Coding Clarity

Reimbursement risk, a key gating factor for medtech adoption, is now largely de-risked for 2026–2027. Both CMS (Medicare) and commercial payers support Genio procedures under established codes, with 100% prior authorization approval rates reported. The WISER program, an AI-based Medicare authorization tool, has also delivered full approval. Looking to 2028, Nyxoah is prepared for either dedicated CPT codes or a broader AGNS code set, mirroring competitor moves and ensuring no technology will be “orphaned” from reimbursement.

3. Gross Margin Recovery Initiatives

Short-term margin pressure from production yield issues is being addressed, with a return to mid-60s gross margin expected by year-end. The Genio 2.2 upgrade, featuring a new low-cost disposable patch and upgraded software (launching early 2027), is positioned to drive a step-change in margin profile to the low 70% range. Volume-based pricing agreements with contract manufacturers are expected to further support the path to 80% gross margin as scale is achieved.

4. Disciplined Cost Management and Capital Allocation

Management is reallocating resources from R&D and G&A to commercial drivers, holding cash operating expenses nearly flat sequentially despite the U.S. ramp. The company expects cash burn to remain controlled, targeting break-even at sub-€150 million revenue and requiring approximately €100 million in total cash to reach that milestone. The ability to leverage 2025’s infrastructure investments into 2026 and beyond is a core part of the cost discipline narrative.

5. International Execution and Break-Even Focus

International markets remain stable, with Germany achieving break-even three years post-launch and new market entries in the UK and Netherlands demonstrating repeatability of the model. The international segment, while secondary to U.S. growth, provides a base of recurring revenue and operational learnings for future expansion.

Key Considerations

This quarter’s results signal a transition from launch to scale in the U.S., with operational levers and reimbursement clarity supporting a robust growth trajectory. Investors should focus on the interplay between commercial expansion, margin recovery, and capital discipline as the company approaches key inflection points.

Key Considerations:

• Commercial Execution Leverage: Success of new sales reps and surgeon onboarding will dictate the pace of U.S. market share gains.
• Margin Inflection Timing: Resolution of yield issues and the Genio 2.2 launch are critical to achieving the targeted margin uplift.
• Reimbursement Durability: Continued payer clarity through 2027–2028 will be essential for sustained adoption and competitive positioning.
• Patient Pipeline Conversion: The doubling of patients submitted for prior authorization underpins near-term revenue visibility, but conversion timing depends on OR capacity at high-volume sites.
• International Replicability: Break-even achieved in Germany provides a template for future international launches and supports overall margin structure.

Risks

Key risks include potential delays in patient conversion due to surgical scheduling bottlenecks at high-volume sites, ongoing gross margin volatility until manufacturing improvements are fully realized, and the risk of reimbursement code changes post-2027 that could impact payer behavior or procedural economics. Competitive dynamics, particularly from larger incumbents seeking dedicated CPT codes, may also shape future market access and pricing power.

Forward Outlook

For Q2 2026, Nyxoah guided to:

• U.S. net revenue growth of 25–30% sequentially
• Continued expansion in account activation and sales rep productivity

For full-year 2026, management raised guidance:

• Worldwide net revenue of €36–40 million
• Gross margin of 60–62%
• Total operating expenses of €97–99 million (non-GAAP cash OPEX: €88–90 million)

Management emphasized:

• Acceleration in revenue growth expected in the back half of 2026 as new reps and trained surgeons ramp productivity
• Reimbursement frameworks remain stable, supporting confidence in guidance and future growth

Takeaways

Nyxoah’s Q2 results validate its U.S. commercial model, with sequential revenue gains and a robust patient pipeline supporting a confident outlook. Margin recovery and disciplined cost management remain central to the investment case as the company scales toward profitability.

• U.S. Commercial Momentum: Expanded sales coverage and surgeon engagement are translating into accelerating adoption and market share gains in targeted accounts.
• Margin and Cost Discipline: Near-term gross margin softness is being actively managed, with product and process upgrades on track to restore profitability as scale builds.
• Watch for 2027–2028 Coding Evolution: Reimbursement clarity is secure through 2027, but investors should monitor developments in AGNS coding and competitive responses as the market matures.

Conclusion

Nyxoah’s Q2 performance underscores strong commercial execution in the U.S. and a disciplined approach to scaling operations. With reimbursement risk largely neutralized and margin recovery initiatives underway, the company is positioned to accelerate growth and move closer to sustainable profitability.

Industry Read-Through

Nyxoah’s experience highlights the critical importance of payer clarity and operational discipline for medtech innovators entering the U.S. market. The rapid ramp in Genio adoption, enabled by targeted sales force expansion and surgeon engagement, sets a benchmark for commercial execution in neurostimulation and other device categories. The evolving AGNS coding landscape, with the prospect of dedicated or comprehensive CPT codes, will be a key watchpoint for all players in the sleep apnea and broader neuromodulation space. Margin recovery strategies—anchored in manufacturing scale and product innovation—will increasingly differentiate winners as the market matures.

NYXH Healthcare Medical Devices Neurostimulation Commercialization Gross Margin Reimbursement Sleep Apnea